In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Legend Biotech Corp ADR (NASDAQ: LEGN) was $31.01 for the day, down -0.53% from the previous closing price of $31.17. In other words, the price has decreased by -$0.53 from its previous closing price. On the day, 2.76 million shares were traded. LEGN stock price reached its highest trading level at $32.66 during the session, while it also had its lowest trading level at $30.67.
Ratios:
Our analysis of LEGN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on October 07, 2025, initiated with a Overweight rating and assigned the stock a target price of $40.
On October 08, 2024, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $86.
On June 17, 2024, Truist started tracking the stock assigning a Buy rating and target price of $88.Truist initiated its Buy rating on June 17, 2024, with a $88 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 26 ’25 when Casey Patrick John bought 1,000 shares for $33.28 per share.
Huang Ying bought 1,370 shares of LEGN for $45,210 on Sep 24 ’25. On Sep 23 ’25, another insider, Huang Ying, who serves as the Officer of the company, bought 1,357 shares for $33.98 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 5727223296 and an Enterprise Value of 10606337024. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.29 while its Price-to-Book (P/B) ratio in mrq is 5.66. Its current Enterprise Value per Revenue stands at 11.668 whereas that against EBITDA is -58.521.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.08, which has changed by -0.18368685 over the last 52 weeks, in comparison to a change of 0.1476624 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $45.30, while it has fallen to a 52-week low of $27.34. The 50-Day Moving Average of the stock is -5.34%, while the 200-Day Moving Average is calculated to be -10.54%.
Shares Statistics:
LEGN traded an average of 1.23M shares per day over the past three months and 1183540 shares per day over the past ten days. A total of 184.69M shares are outstanding, with a floating share count of 180.89M. Insiders hold about 2.06% of the company’s shares, while institutions hold 44.95% stake in the company. Shares short for LEGN as of 1761868800 were 10772670 with a Short Ratio of 8.79, compared to 1759190400 on 9351983. Therefore, it implies a Short% of Shares Outstanding of 10772670 and a Short% of Float of 11.16.
Earnings Estimates
. The current rating of Legend Biotech Corp ADR (LEGN) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between -$0.2 and -$1.46 for the fiscal current year, implying an average EPS of -$0.79. EPS for the following year is $0.56, with 8.0 analysts recommending between $0.99 and $0.28.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 8 analysts. It ranges from a high estimate of $368.26M to a low estimate of $304M. As of. The current estimate, Legend Biotech Corp ADR’s year-ago sales were $186.52MFor the next quarter, 8 analysts are estimating revenue of $306.44M. There is a high estimate of $317.5M for the next quarter, whereas the lowest estimate is $300M.
A total of 12 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.02B, resulting in an average revenue estimate of $1.04B. In the same quarter a year ago, actual revenue was $627.24MBased on 14 analysts’ estimates, the company’s revenue will be $1.55B in the next fiscal year. The high estimate is $1.91B and the low estimate is $1.37B.
